FIELD: medicine.
SUBSTANCE: invention claims antibodies, which specifically bind with IL-13. Also claimed are nucleic acids, encoding antibodies, expression vectors, containing sequences of said nucleic acids, as well as cells, containing such cells. In addition claimed is method of diagnosing associated with IL-13 disorders, method of obtaining molecule of recombinant antibody, method of treating disorder, associated with IL-13 activity, method of determining IL-13 in sample and method of treating subject, demonstrating asthma attack.
EFFECT: invention can be efficiently applied in diagnostics and treatment of IL-13 mediated disorders.
116 cl, 16 dwg, 4 tbl, 21 ex
| Title | Year | Author | Number |
|---|---|---|---|
| HUMANISED ANTIBODY (H14,18) BASED ON MOUSE ANTIBODY 14,18, CONTACTING GD2, AND ITS FUSION WITH IL-2 | 2003 |
|
RU2366664C2 |
| HUMAN INTERLEUKIN-13 ANTIBODIES AND THEIR APPLICATION | 2005 |
|
RU2427589C2 |
| HUMANISED ANTI-LIGHT ANTIBODIES AND USING THEM | 2010 |
|
RU2542394C2 |
| RECOMBINANT SPECIFIC ANTIBODY (VARIANTS) AND USES THEREOF | 2002 |
|
RU2306320C9 |
| IMPROVED EXPRESSION VECTORS OF MAMMALS AND THEIR USE | 2009 |
|
RU2502800C2 |
| IL-17 ANTAGONIST ANTIBODIES | 2005 |
|
RU2426741C2 |
| MONOCLONAL ANTIBODY TO IL-5RΑ | 2017 |
|
RU2698048C2 |
| gp41-NEUTRALIZING ANTIBODIES AND THEIR APPLICATION | 2012 |
|
RU2624046C2 |
| RECOVERED HUMAN ANTIBODY OR ITS ANTIGEN-BINDING FRAGMENT (VERSIONS), METHOD OF TREATING hTNFα-MEDIATED DISEASES WITH MEDIATION THEREOF (VERSIONS), PHARMACEUTICAL COMPOSITION, RECOMBINANT HUMAN ANTIBODY OR ITS ANTIGEN-BINDING FRAGMENT, RECOVERED NUCLEIC ACID (VERSIONS) | 2005 |
|
RU2458704C9 |
| ANTIBODIES AGAINST NERVE GROWTH FACTOR AND METHODS FOR THEIR PRODUCTION AND APPLICATION | 2012 |
|
RU2644235C2 |
